Evozyne is a biotechnology company that harnesses the power of evolution to create novel proteins aimed at addressing challenges in therapeutic development. The company focuses on enhancing protein performance to enable commercial-scale solutions for new products and contribute to a healthier world.

Evozyne

Evozyne combines evolution and deep learning technology to create highly functional novel proteins — Natural Machines™ — to solve longstanding challenges in therapeutics and sustainability. By amplifying a protein’s function based on the rules of nature, we address complex, high-impact problems.  From developing life-changing patient treatments to making carbon capture a reality, Evozyne is committed to making a healthier, more sustainable world. 

Fidelity Management and Research Company

Valor Equity Partners

NVentures

OrbiMed

Paragon Biosciences

Today, we honor the life and legacy of Dr. Martin Luther King, Jr. His dream of a united, compassionate world where kindness prevails, and equality thrives continues to live on. #martinlutherkingjr 

Great news to start 2024! Biotech veteran Marc Yoskowitz joins Evozyne as our new CEO. He will be leading Evozyne as we focus on drug discovery through our generative AI platform.

Read more: https://lnkd.in/g2_bnHCF

#ceo 

Evozyne was recently featured in Chicago NBC 5 news story on AI drug development. The segment, featuring CEO Mike Gamson, highlighted the potential of AI to expedite new therapies and cures for those who need it the most, saving time, money and potentially lives. 

Check it out: https://lnkd.in/gJcJHnEg
 
#ai #drugdevelopment  

COM:EVOZYNE

Evozyne

Financials Not Available